新疆天山畜牧生物工程股份有限公司 关于延期回复深圳证券交易所年报问询函的公告 公司董事会对此次延期回复给投资者带来的不便致以诚挚的歉意，敬请广大 投资者谅解。公司指定的信息披露媒体为《证券时报》《上海证券报》及巨潮资 讯网(http://www.cninfo.com.cn)，公司所有信息均以公司在上述媒体刊登的公 告为准。敬请投资者关注，注意投资风险。 特此公告。 新疆天山畜牧生物工程股份有限公司董事会 证券代码：300313 证券简称：*ST天山 公告编号：2024-038 二〇二四年五月十六日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日收到深圳证券交易所创业板公司管理部《关于对新疆天山畜牧生物工程股 份有限公司的年报问询函》（创业板年报问询函〔2024〕第 13 号，以下简称"年 报问询函"）,要求公司就相关事项做出书面说明，在 2024 年 4 月 30 日前将有 关说明材料报送深圳证券交易所创业板公司管理部并对外披露。 公司收到《年报问询函》后高度重视，立即组织 ...

证券代码：300313 证券简称：*ST天山 公告编号：2024-036 特此公告。 新疆天山畜牧生物工程股份有限公司 关于延期回复深圳证券交易所年报问询函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日收到深圳证券交易所创业板公司管理部《关于对新疆天山畜牧生物工程股 份有限公司的年报问询函》（创业板年报问询函〔2024〕第 13 号，以下简称"年 报问询函"）,要求公司就相关事项做出书面说明，在 2024 年 4 月 30 日前将有 关说明材料报送深圳证券交易所创业板公司管理部并对外披露。 公司收到《年报问询函》后高度重视，立即组织相关部门及协调相关机构对 《年报问询函》所涉问题进行逐项落实、核查与回复。鉴于《年报问询函》涉及 的部分内容细节尚需进一步补充和完善，为确保回复内容及信息披露的内容真实、 准确、完整，经公司向深圳证券交易所申请,公司将延期至 2024 年 5 月 17 日前 完成回复工作，并及时履行信息披露义务。 公司董事会对此次延期回复给投资者带来的不 ...

证券代码：300313 证券简称：*ST天山 公告编号：2024-037 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、2024 年 4 月销售情况简报 新疆天山畜牧生物工程股份有限公司 2024 年 4 月活畜销售情况简报 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）2024 年 4 月销 售活畜 211 头，销售收入 153.11 万元，环比变动分别为-69.20%、-81.71%；同 比变动分别为 95.37%、-36.64%。 二、原因说明 活畜业务中，不同用途和客户需求不同的牛只养殖周期存在差异，公司会根 据生产经营规划和市场行情变化趋势适当调整出栏时间。本月活畜销售数量、销 售收入环比减少的主要原因是本月出栏牛只数量低于上月；活畜销售数量、销售 收入同比变动的主要原因是本月销售的大部分为均价较低的退役母牛所致。 三、风险提示 （一）上述数据未经审计，可能与公司定期报告披露的数据存在差异，因此 上述数据仅作为阶段性数据供投资者参考。 （二）上述披露仅包含公司活畜销售情况，不含其它业务。 （三）《证券时报》《上海证券报》以及巨潮资讯网（w ...

北京市君致律师事务所 关于新疆天山畜牧生物工程股份有限公司 2023 年度股东大会的 法 律 意 见 书 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编：100013 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC 电话（Tel）：010-52213236 网址（Website）：www.junzhilawyer.com 法律意见书 北京市君致律师事务所 关于新疆天山畜牧生物工程股份有限公司 2023 年度股东大会的法律意见书 致：新疆天山畜牧生物工程股份有限公司 北京市君致律师事务所（以下简称"本所"）接受新疆天山畜牧生物工程股 份有限公司（以下简称"公司"）的委托，指派本所律师出席公司 2023 年度股 东大会（以下简称"本次股东大会"）进行见证并出具法律意见。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以 下简称"《股 ...

Financial Performance - The company's revenue for Q1 2024 was ¥17,543,154.91, a decrease of 24.24% compared to ¥23,156,538.66 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥7,206,692.62, representing a decline of 79.45% from a loss of ¥4,015,972.23 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 17,543,154.91, a decrease of 24.8% compared to CNY 23,156,538.66 in the same period last year[39] - Net loss for Q1 2024 was CNY 6,826,573.04, compared to a net loss of CNY 4,187,542.06 in Q1 2023, representing an increase in loss of 63.0%[40] - Total operating costs for Q1 2024 were CNY 24,744,512.43, down 10.1% from CNY 27,560,427.12 year-over-year[39] Cash Flow and Liquidity - The net cash flow from operating activities increased by 1.65% to ¥5,424,757.22, compared to ¥5,336,772.76 in the same period last year[5] - The cash inflow from operating activities increased by 42.61% to ¥30,809,346.05, while cash outflow increased by 56.05% to ¥25,384,588.83[11] - The company's cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[41] - Cash received from sales of goods and services was $29,216,076.99, up from $20,969,025.16 in the previous period[42] - The ending balance of cash and cash equivalents was $22,446,910.25, down from $45,331,434.33 in the previous period[43] Assets and Liabilities - The total assets at the end of the reporting period were ¥313,554,522.36, a slight decrease of 0.53% from ¥315,229,860.70 at the end of the previous year[5] - Total liabilities increased to ¥248,142,997.32 from ¥243,236,762.62, an increase of 2.0%[38] - The company's total assets decreased to CNY 313,554,522.36 from CNY 315,229,860.70, a decline of 0.5%[38] - The company's equity attributable to shareholders decreased by 11.59% to ¥54,961,943.41 from ¥62,168,636.03 at the end of the previous year[5] - The total equity attributable to shareholders decreased to CNY 54,961,943.41 from CNY 62,168,636.03, a decline of 11.5%[38] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,169[13] - The top shareholder, Huzhou Haohui Enterprise Management Consulting Co., Ltd., holds 22.11% of the shares, amounting to 69,211,312 shares[13] - The controlling shareholder, Huzhou Haohui, signed a framework agreement to transfer control of 40,718,359 shares, representing 13.01% of the total shares, to China Electric Power Agricultural Innovation Technology Co., Ltd. (CEPA) [16] - As of the report date, Huzhou Haohui holds 69,211,312 shares, accounting for 22.11% of the total share capital, with 15,350,000 shares pledged, which is 22.18% of its holdings and 4.90% of the total share capital [20] - Chen Dehong holds 37,279,083 shares, representing 11.91% of the total share capital, with 36,509,768 shares pledged, which is 97.94% of his holdings and 11.67% of the total share capital [22] Legal Proceedings - The company is involved in ongoing legal proceedings related to the acquisition of Elephant Advertising, with significant shares expected to be returned following court rulings [19] - The company is involved in ongoing legal proceedings related to contract fraud, with significant financial implications from the case against Daxiang Advertising Co., Ltd. and its representatives[29] - The court has ruled to confiscate shares held by 30 defendants in the ongoing fraud case, with further actions pending regarding the return of these shares[30] - The company is actively pursuing the recovery of shares involved in legal disputes, with ongoing updates to be disclosed as the situation progresses[30] - The company has faced challenges related to stock pledges by former executives, with ongoing legal disputes regarding the validity of these pledges[33] Strategic Decisions and Future Plans - The company plans to liquidate and deregister its subsidiary Ningxia Meijia Agricultural Biotechnology Co., Ltd. due to unclear strategic direction and continuous losses, with net assets declining year by year[26] - A joint venture company named Guangdong Tiansheng Agricultural Technology Co., Ltd. was established with a registered capital of CNY 10 million, focusing on the beef supply chain in the Greater Bay Area and other regions[28] - The company aims to optimize resource allocation and reduce management costs through strategic decisions, including the liquidation of underperforming subsidiaries[26] - The company plans to enhance market expansion strategies and invest in new technologies to improve future performance[41] Investment and Income - The company reported a significant increase in investment income, rising by 115.40% to ¥1,140,575.71 from ¥529,509.64 in the previous year[10] - Cash inflow from investment activities totaled $1,454,790.00, compared to $148,172.00 in the previous period, marking a significant increase[43] - Net cash flow from investment activities improved to $1,344,790.00 from a negative $733,333.00 in the prior period[43] Research and Development - Research and development expenses rose to CNY 212,759.43 from CNY 181,359.78, an increase of 17.3% year-over-year, indicating a focus on innovation[40]

证券代码：300313 证券简称：*ST天山 公告编号：2024-033 新疆天山畜牧生物工程股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会不存在否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 本次股东大会采用现场记名投票与网络投票相结合的方式进行表决，与会股东 及股东代表审议了下列议案，形成如下决议： 提案 1.00 《公司 2023 年年度报告及摘要》 总表决情况：同意 105,646,110 股，占出席会议所有股东所持股份的 99.9947%； 反对 5,600 股，占出席会议所有股东所持股份的 0.0053%；弃权 0 股（其中，因未 投票默认弃权 0 股），占出席会议所有股东所持股份的 0.0000％。 一、会议召开和出席情况 新疆天山畜牧生物工程股份有限公司(以下简称"公司")董事会于 2024 年 3 月 30 日以公告形式向全体股东发出召开 2023 年度股东大会的通知，本次股东大会 采取现场投票及网络投票相结合的方式召开。 本次现场会议于 20 ...

深 圳 证 券 交 易 所 关于对新疆天山畜牧生物工程股份有限 公司 2023 年年报的问询函 创业板年报问询函〔2024〕第 13 号 新疆天山畜牧生物工程股份有限公司董事会： 我部在对你公司 2023 年度报告（以下简称"年报"） 进行事后审查的过程中，关注到以下情况： （1）说明报告期活畜业务的具体内容，并按活畜业务 客户列示相关合同中关于公司向上游采购定价、存货风险分 担、向下游销售定价等方面的约定和实际执行情况以及主要 经营过程； （2）结合前述情况及业务模式等,说明活畜业务毛利率 1 为负值的原因及合理性，说明该业务定价是否公允，是否存 在明显低于市场价格销售以扩大销售收入等情形，在此基础 上说明该业务是否实质为贸易业务，是否具备商业实质，该 业务收入确认及扣除是否符合企业会计准则及营业收入扣 除的有关规定； （3）说明活畜业务、资产租赁业务、冻精业务报告期 收入增长的原因及合理性； （4）说明报告期你公司上述各项业务采用的收入确认 方法和依据，以及是否符合会计准则的有关规定。 2.年报显示，报告期内，你公司资产租赁业务实现营业 收入 2,698.65 万元，毛利率分别上升 15.49%。请你公司 ...

证券代码：300313 证券简称：*ST天山 公告编号：2024-032 新疆天山畜牧生物工程股份有限公司 2024 年 3 月活畜销售情况简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、2024 年 3 月销售情况简报 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）2024 年 3 月销 售活畜 685 头，销售收入 837.15 万元，环比变动分别为 1041.67%、1708.40%； 同比变动分别为 69.14%、16.07%。 二、原因说明 活畜业务中，不同用途和客户需求不同的牛只养殖周期存在差异，公司也会 根据生产经营规划和市场行情变化趋势适当调整出栏时间。本月活畜销售数量和 销售收入环比、同比增加的主要原因是本月出栏牛只数量高于上月及去年同期。 三、风险提示 特此公告。 新疆天山畜牧生物工程股份有限公司董事会 二〇二四年四月九日 （一）上述数据未经审计，可能与公司定期报告披露的数据存在差异，因此 上述数据仅作为阶段性数据供投资者参考。 （二）上述披露仅包含公司活畜销售情况，不含其它业务。 （三）《证券时报》《上海证券报》以及巨潮资 ...

Financial Performance - The company reported a net loss of 7.2175 million yuan due to significant impairment of consumable biological assets and depreciation costs exceeding revenue from low-efficiency assets[3]. - The company's operating revenue for 2023 reached ¥137,499,875.86, representing an increase of 80.09% compared to ¥76,350,268.21 in 2022[23]. - The net profit attributable to shareholders was a loss of ¥22,001,636.31, an improvement of 30.88% from a loss of ¥31,848,222.21 in the previous year[23]. - The net cash flow from operating activities was negative at ¥13,747,711.18, which is a decline of 81.71% compared to ¥-7,565,896.10 in 2022[23]. - The total assets at the end of 2023 were ¥315,229,860.70, down 5.22% from ¥332,145,607.55 at the end of 2022[23]. - The net assets attributable to shareholders decreased by 26.14% to ¥62,168,636.03 from ¥84,261,480.39 in 2022[23]. - The company reported a basic earnings per share of -¥0.07, an improvement of 30.00% from -¥0.10 in 2022[23]. - The company reported an operating loss of 18.66 million yuan, a year-on-year reduction in losses of 33.92%[66]. - The company reported a negative net profit for 2023, which may lead to continued risk warnings under the Shenzhen Stock Exchange regulations[113]. Audit and Compliance - The financial report received an unqualified audit opinion with emphasis on matters related to going concern uncertainties[3]. - The company continues to face uncertainty regarding its ability to continue as a going concern, as indicated in the recent audit report[24]. - The board respects the audit report issued by Zhongxing Caiguanghua Accounting Firm, which includes a significant uncertainty regarding the company's ability to continue as a going concern[198]. - The company has maintained independence in operations, assets, personnel, and finance since its establishment, ensuring a complete production, sales, and R&D system[130]. - The company has not reported any violations regarding external guarantees during the reporting period[187]. Operational Developments - The company operates primarily in the livestock industry, with approximately 80% of its business focused on cattle breeding and beef cattle farming[35]. - The company is expanding its operations into the beef cattle fattening industry, leveraging its breeding advantages and improving existing ranch facilities[49]. - The company aims to enhance digital management in cattle breeding and slaughtering, establishing a big data platform for the beef cattle industry in Tongliao[47]. - The company has established a modern breeding system integrating breeding, prevention, nutrition, and scientific feeding, providing comprehensive services to cattle farmers[48]. - The company is focused on establishing a stable supply network for healthy beef in key regions such as Beijing and the Yangtze River Delta[110]. Market Conditions - The average price of fattened cattle in June 2023 dropped to approximately 25.39 yuan/kg, the lowest since November 2017, reflecting a significant decline in market prices[42]. - The beef cattle industry is experiencing cyclical fluctuations, with many large-scale breeding enterprises reporting significant losses due to declining market conditions in 2023[42]. - The company is expanding its beef cattle breeding operations in Xinjiang to counteract market fluctuations and price declines[68]. - The company recognizes the cyclical nature of the livestock industry and aims to create a closed-loop industry chain to mitigate risks associated with market fluctuations[115]. Strategic Initiatives - The company plans to focus on the Chinese beef cattle industry, implementing a "big beef cattle strategy" to strengthen breeding and beef cattle farming[104]. - The company aims to provide high-quality frozen semen and embryos, enhancing genetic material and related technical services for the livestock industry[104]. - The company has initiated a breeding alliance to enhance the independent innovation capability of China's beef cattle industry[48]. - The company is actively participating in policy-driven initiatives to support high-quality development in the beef cattle industry, including digitalization and standardization efforts[46]. Governance and Management - The board of directors consists of 9 members, with independent directors making up at least one-third, ensuring compliance with governance standards[126]. - The company has a new management team with diverse backgrounds in finance, law, and livestock management[136][137][138]. - The company has implemented a long-term training mechanism to improve management capabilities and operational control across subsidiaries[119]. - The company has held multiple shareholder meetings in 2023, with attendance rates ranging from 12.05% to 35.10%[131]. Social Responsibility and Sustainability - The company has actively engaged in social responsibility initiatives, linking industry development with rural revitalization[168]. - The company has complied with environmental regulations and has not faced any administrative penalties related to environmental issues[167]. - The company has committed to sustainability initiatives, planning to invest 50 million yuan in eco-friendly practices[178]. - The company aims to achieve carbon neutrality by 2025, aligning with global sustainability trends[184]. Legal and Financial Risks - The company is involved in a legal case regarding the original actual controller's contract fraud, with a final ruling resulting in the confiscation of 37,279,083 shares held by the controller and 78,345,524 shares held by 35 shareholders[189]. - The company is actively pursuing the recovery of shares held by the original actual controller of Daxiang Advertising, who was involved in a contract fraud case[197]. - The company has faced significant uncertainties regarding its ability to continue as a going concern due to declining revenues and substantial losses[188]. - The company will take necessary measures to address the impacts of the legal issues and financial adjustments on its operations[190].

根据《公司法》和《公司章程》的有关规定，经新疆天山畜牧生物工程股份 有限公司（以下简称"公司"）第五届董事会第四次会议审议通过，公司决定于 2024 年 4 月 23 日在新疆昌吉市宁边西路 262 号公司会议室召开 2023 年度股东 大会。现将会议有关事项通知如下： 证券代码：300313 证券简称：*ST天山 公告编号：2024-028 新疆天山畜牧生物工程股份有限公司 关于召开 2023 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年度股东大会。 2、股东会议的召集人：董事会。 3、会议召开的合法、合规性：经第五届董事会第四次会议审议通过，公司 召开 2023 年度股东大会；本次股东大会会议的召开符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 4 月 23 日下午 15:00（北京时间）。 （2）网络投票时间： 1）通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 4 月 23 日上 ...